HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Beaumier, P. L. Articles by Larson, S. M. Search for Related Content PubMed PubMed Citation Articles by Beaumier, P. L. Articles by Larson, S. M.

Melanoma Localization in Nude Mice with Monoclonal Fab Against p97

University of Washington School of Medicine, Oncogen, Seattle, WA
Department of Nuclear Medicine, National Institutes of Health, Bethesda, Maryland

Correspondence: For reprints contact: Paul L. Beaumier, PhD, Oncogen, 3005 First Ave., Seattle, WA 98121.

ABSTRACT

The tumor targeting capacity of monoclonal antibody Fab fragments was explored in nude mice bearing human melanoma xenografts. Redioiodinated Fab 8.2 and 96.5, specific for melanoma-associated antigen p97, were tested in vitro for immunoreactivity and in vivo for tumor localization relative to a co-administered control, Fab 1.4. Fab was cleared rapidly from the blood with a T_1/2 of 3–3.5 hr and >90% of the injected radioactivity was excreted by 16 hr. The mean specific Feb in tumor reached a maximum of 3.5% injected dose/g at 4 hr and decreased to 1.5% at 16 hr. Over the same period, the ratio of specific/control Feb in tumor normalized to blood, the localization index, rose from 3 to 25 compared with ratios near unity for all other tissues. The concentration of specific Fab in tumor could be correlated to the amount of Fab protein administered as well as its immunoreactivity.

This article has been cited by other articles:

				J. R. Podojil, A. P. Kohm, and S. D. Miller CD4+ T Cell Expressed CD80 Regulates Central Nervous System Effector Function and Survival during Experimental Autoimmune Encephalomyelitis. J. Immunol., September 1, 2006; 177(5): 2948 - 2958. [Abstract] [Full Text] [PDF]

				S. Froidevaux, M. Calame-Christe, H. Tanner, L. Sumanovski, and A. N. Eberle A Novel DOTA-{alpha}-Melanocyte-Stimulating Hormone Analog for Metastatic Melanoma Diagnosis J. Nucl. Med., December 1, 2002; 43(12): 1699 - 1706. [Abstract] [Full Text] [PDF]